Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1866 USD
−13.00 M USD
1.34 M USD
52.67 M
About IGC Pharma, Inc.
Sector
Industry
CEO
Ram Mukunda
Website
Headquarters
Potomac
Founded
2005
FIGI
BBG000NSSLY8
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IGC is 0.3525 USD — it has decreased by −2.86% in the past 24 hours. Watch IGC Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange IGC Pharma, Inc. stocks are traded under the ticker IGC.
IGC stock has fallen by −7.62% compared to the previous week, the month change is a −16.68% fall, over the last year IGC Pharma, Inc. has showed a 10.85% increase.
We've gathered analysts' opinions on IGC Pharma, Inc. future price: according to them, IGC price has a max estimate of 3.75 USD and a min estimate of 3.75 USD. Watch IGC chart and read a more detailed IGC Pharma, Inc. stock forecast: see what analysts think of IGC Pharma, Inc. and suggest that you do with its stocks.
IGC stock is 8.66% volatile and has beta coefficient of 0.14. Track IGC Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is IGC Pharma, Inc. there?
Today IGC Pharma, Inc. has the market capitalization of 25.81 M, it has decreased by −6.82% over the last week.
Yes, you can track IGC Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
IGC Pharma, Inc. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
IGC earnings for the last quarter are −0.02 USD per share, whereas the estimation was −0.03 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.03 USD per share. See more details about IGC Pharma, Inc. earnings.
IGC Pharma, Inc. revenue for the last quarter amounts to 412.00 K USD, despite the estimated figure of 291.00 K USD. In the next quarter, revenue is expected to reach 204.00 K USD.
IGC net income for the last quarter is −1.72 M USD, while the quarter before that showed −2.38 M USD of net income which accounts for 27.80% change. Track more IGC Pharma, Inc. financial stats to get the full picture.
No, IGC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 67.00 employees. See our rating of the largest employees — is IGC Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IGC Pharma, Inc. EBITDA is −8.67 M USD, and current EBITDA margin is −681.12%. See more stats in IGC Pharma, Inc. financial statements.
Like other stocks, IGC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IGC Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IGC Pharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IGC Pharma, Inc. stock shows the strong sell signal. See more of IGC Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.